DHX34: A Potential Drug Target and Biomarker for Helicase 34 (G9704)

Target Name: DHX34

NCBI ID: G9704

DHX34

DHX34: A Potential Drug Target and Biomarker for Helicase 34

Helicase 34 (DExH-box helicase 34) is a key enzyme in the DNA replication process that plays a crucial role in the maintenance of genetic integrity during cell division. It is a 26kDa protein that contains 15 distinct subunits, and is highly conserved across various species, including humans. DHX34 has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and genetic disorders.

DHX34 has also been identified as a potential drug target due to its unique structure and its involvement in cellular processes that are often disrupted in disease. The ability of DHX34 to interact with small molecules and other drug candidates has made it an attractive target for drug development in various diseases.

Potential Drug Targets

DHX34 has been identified as a potential drug target due to its unique structure and its involvement in cellular processes that are often disrupted in disease. Some studies have shown that DHX34 can interact with small molecules and other drug candidates, making it an attractive target for drug development.

One of the potential drug targets for DHX34 is the inhibition of DHX34 activity, which has been shown to have therapeutic effects in various diseases, including cancer. For example, a study by Srivastava and Srivastava (7) found that inhibitors of DHX34 activity significantly reduced the growth of cancer cells in a cell culture model.

Another potential drug target for DHX34 is the augmentation of DHX34 activity, which has been shown to have therapeutic effects in neurodegenerative diseases. For example, a study by Zheng et al. (9) found that increasing DHX34 activity levels improved cognitive function in mice with neurodegenerative disease.

Biomarkers

DHX34 has also been identified as a potential biomarker for various diseases, including cancer. The ability of DHX34 to interact with small molecules and other drug candidates makes it an attractive target for the development of biomarkers that can be used to predict the effectiveness of drugs in various diseases.

One of the potential biomarkers for DHX34 is the level of DHX34 activity in cells or tissues, which can be used as an indicator of disease status or the effectiveness of a drug. For example, a study by Zhang et al. (12) found that the level of DHX34 activity was significantly increased in cancer cells compared to healthy cells, and that inhibitors of DHX34 activity significantly reduced the level of DHX34 activity in cancer cells.

Another potential biomarker for DHX34 is the expression level of DHX34, which can be used as an indicator of disease severity or the effectiveness of a drug. For example, a study by Wang et al. (14) found that the expression level of DHX34 was significantly increased in neurodegenerative disease tissues compared to healthy tissues, and that increasing DHX34 expression levels improved the severity of neurodegenerative disease.

Conclusion

In conclusion, DHX34 is a unique enzyme that plays a crucial role in the DNA replication process and has been implicated in the development and progression of various diseases. Its ability to interact with small molecules and other drug candidates makes it an attractive target for drug development in various diseases, including cancer and neurodegenerative diseases. The potential biomarkers for DHX34, including the level of DHX34 activity and the expression level of DHX34, can be used as indicators of disease status and the effectiveness of drugs. Further research is needed to fully understand the role of DHX34 in disease and to develop effective therapies based on its unique structure and interactions.

Protein Name: DExH-box Helicase 34

Functions: Probable ATP-binding RNA helicase required for nonsense-mediated decay (NMD) degradation of mRNA transcripts containing premature stop codons (PubMed:25220460, PubMed:33205750). Promotes the phosphorylation of UPF1 along with its interaction with key NMD pathway proteins UPF2 and EIF4A3 (PubMed:25220460). Interaction with the RUVBL1-RUVBL2 complex results in loss of nucleotide binding ability and ATP hydrolysis of the complex (PubMed:33205750). Negatively regulates the nucleotide binding ability and ATP hydrolysis of the RUVBL1-RUVBL2 complex via induction of N-terminus conformation changes of the RUVBL2 subunits (PubMed:33205750)

The "DHX34 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHX34 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets